Literature DB >> 22239576

From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments.

O D Howes1, P Fusar-Poli, M Bloomfield, S Selvaraj, P McGuire.   

Abstract

Schizophrenia is a chronic psychotic disorder that remains a considerable cause of global disease burden. Cognitive impairments are common and contribute significantly to the morbidity of the disorder. Over the last two decades or so molecular imaging studies have refined understanding of the pathophysiology underlying the development of psychosis and cognitive impairments. Firstly they have consistently implicated presynaptic dopaminergic dysfunction in the disorder, finding that dopamine synthesis capacity, dopamine release and baseline dopamine levels are increased in the illness. Secondly recent findings show that dopamine synthesis capacity is elevated in those that go on to develop psychosis in the following year, but not in those that do not, and appears to increase further with the development of psychosis. Thirdly evidence links greater dopamine synthesis capacity to poorer cognitive performance and altered frontal cortical function measured using functional imaging during cognitive tasks. Finally they have provided data on the nature of other neurofunctional alterations in the disorder, in particular in the serotonergic system and neuroinflammation. We review these findings and discuss their implications for understanding the neurobiology of psychosis and cognitive impairments in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22239576      PMCID: PMC3662992          DOI: 10.2174/138161212799316217

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  95 in total

Review 1.  Epidemiology of schizophrenia: the global burden of disease and disability.

Authors:  A Jablensky
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2000       Impact factor: 5.270

2.  Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study.

Authors:  A Jablensky; N Sartorius; G Ernberg; M Anker; A Korten; J E Cooper; R Day; A Bertelsen
Journal:  Psychol Med Monogr Suppl       Date:  1992

3.  Imaging changes in glutamate transmission in vivo with the metabotropic glutamate receptor 5 tracer [11C] ABP688 and N-acetylcysteine challenge.

Authors:  Nobumi Miyake; Mette Skinbjerg; Balu Easwaramoorthy; Dileep Kumar; Ragy R Girgis; Xiaoyan Xu; Mark Slifstein; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2011-02-02       Impact factor: 13.382

4.  'Truman' signs and vulnerability to psychosis.

Authors:  Paolo Fusar-Poli; Oliver Howes; Lucia Valmaggia; Philip McGuire
Journal:  Br J Psychiatry       Date:  2008-08       Impact factor: 9.319

5.  Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics.

Authors:  K Radewicz; L J Garey; S M Gentleman; R Reynolds
Journal:  J Neuropathol Exp Neurol       Date:  2000-02       Impact factor: 3.685

6.  Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

7.  Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis.

Authors:  James M Stone; Oliver D Howes; Alice Egerton; Joseph Kambeitz; Paul Allen; David J Lythgoe; Ruth L O'Gorman; Mary A McLean; Gareth J Barker; Philip McGuire
Journal:  Biol Psychiatry       Date:  2010-07-17       Impact factor: 13.382

8.  The global costs of schizophrenia.

Authors:  Martin Knapp; Roshni Mangalore; Judit Simon
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

9.  Provocative tests with psychostimulant drugs in schizophrenia.

Authors:  J A Lieberman; J M Kane; J Alvir
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

10.  Decreased 5-HT1A receptor binding in amygdala of schizophrenia.

Authors:  Fumihiko Yasuno; Tetsuya Suhara; Tetsuya Ichimiya; Akihiro Takano; Tomomichi Ando; Yoshiro Okubo
Journal:  Biol Psychiatry       Date:  2004-03-01       Impact factor: 13.382

View more
  17 in total

1.  Studying auditory verbal hallucinations using the RDoC framework.

Authors:  Judith M Ford
Journal:  Psychophysiology       Date:  2016-03       Impact factor: 4.016

Review 2.  Perinatal Risks and Childhood Premorbid Indicators of Later Psychosis: Next Steps for Early Psychosocial Interventions.

Authors:  Cindy H Liu; Matcheri S Keshavan; Ed Tronick; Larry J Seidman
Journal:  Schizophr Bull       Date:  2015-04-22       Impact factor: 9.306

3.  Prediction and prevention of psychosis: current progress and future tasks.

Authors:  Stephan Ruhrmann; Frauke Schultze-Lutter; Stefanie J Schmidt; Nathalie Kaiser; Joachim Klosterkötter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-26       Impact factor: 5.270

4.  Examining associations between psychosis risk, social anhedonia, and performance of striatum-related behavioral tasks.

Authors:  Nicole R Karcher; Elizabeth A Martin; John G Kerns
Journal:  J Abnorm Psychol       Date:  2015-08

5.  Functional Connectivity of the Striatum in Schizophrenia and Psychotic Bipolar Disorder.

Authors:  Nicole R Karcher; Baxter P Rogers; Neil D Woodward
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-06-12

Review 6.  A review of anti-inflammatory agents for symptoms of schizophrenia.

Authors:  William R Keller; Lionel M Kum; Heidi J Wehring; Maju Mathew Koola; Robert W Buchanan; Deanna L Kelly
Journal:  J Psychopharmacol       Date:  2012-11-13       Impact factor: 4.153

Review 7.  The hypocretin system and psychiatric disorders.

Authors:  Fabio Pizza; Michele Magnani; Camilla Indrio; Giuseppe Plazzi
Journal:  Curr Psychiatry Rep       Date:  2014-02       Impact factor: 5.285

8.  Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis?

Authors:  Emre Bora; Robin M Murray
Journal:  Schizophr Bull       Date:  2013-06-14       Impact factor: 9.306

9.  Association of the brain-derived neurotrophic factor gene G196A rs6265 polymorphisms and the cognitive function and clinical symptoms of schizophrenia.

Authors:  Jinguo Zhai; Qing Yu; Min Chen; Yan Gao; Qiumei Zhang; Jun Li; Keqin Wang; Feng Ji; Zhonghua Su; Wu Li; Xuemei Li; Juyao Qiao
Journal:  Int J Clin Exp Pathol       Date:  2013-07-15

Review 10.  Glutamate and dopamine in schizophrenia: an update for the 21st century.

Authors:  Oliver Howes; Rob McCutcheon; James Stone
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.